当前与新兴猴痘疫苗策略:一项综合综述
猴痘病毒(MPXV)为与天花病毒近缘的人兽共患正痘病毒,1958年发现、1970年首次记录人间病例,近期全球暴发凸显疫苗策略需求。已获批的ACAM2000与MVA-BN可有效预防MPXV感染,MVA-BN对免疫低下者安全性更优;mRNA与多价疫苗等新兴平台显示增强免疫应答的潜力,但可及性、安全性与可扩展性仍存缺口。
要点
- ACAM2000与MVA-BN已获批并显示预防MPXV感染的效力,MVA-BN安全性更优。
- mRNA与多价疫苗等新兴平台在临床前研究中显示增强免疫应答的潜力。
- 当前疫苗策略仍存在可及性、安全性与可扩展性缺口。
核心结论
- 当前MPXV疫苗接种策略为疫情控制提供基础工具,但在可及性、安全性与可扩展性方面仍存缺口,公平分配与研发投入对应对全球猴痘威胁至关重要。
研究设计与样本
- 综合综述,围绕MPXV的病毒学背景、已获批疫苗与新兴疫苗平台进行汇总分析。
主要发现
- MPXV为双链DNA病毒,属正痘病毒属,与痘苗病毒、牛痘病毒同属,1958年发现、1970年首次记录人间病例,起源未定,非洲啮齿类如火足绳松鼠与非人灵长类为潜在宿主。
- 已获批疫苗ACAM2000与MVA-BN在预防MPXV感染中显示效力,MVA-BN对免疫低下个体提供更安全的选择。
- mRNA与多价疫苗等新兴平台在增强免疫应答与克服传统疫苗局限方面显示前景,临床前研究显示快速部署技术可诱导针对MPXV的体液与细胞免疫。
局限性
- 原文指出当前MPXV疫苗策略在可及性、安全性与可扩展性方面仍存缺口。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monkeypox virus (MPXV), a zoonotic orthopoxvirus closely related to variola virus, is a double-stranded DNA (dsDNA) virus in the Orthopoxvirus genus, which includes vaccinia and cowpox viruses. Identified in 1958 and first documented in humans in 1970, MPXV poses substantial public health challenges. Its origins remain uncertain, but African rodents like fire-footed rope squirrels and non-human primates are potential reservoirs. Recent global outbreaks have highlighted the urgent need for effective vaccination strategies to mitigate morbidity, mortality, and transmission risks. Approved vaccines such as ACAM2000 and MVA-BN demonstrate efficacy in preventing MPXV infection, with MVA-BN offering a safer profile, particularly for immunocompromised individuals. Emerging platforms, including mRNA and multivalent vaccines, show promise in enhancing immune responses and addressing limitations of traditional vaccines. Preclinical studies highlight significant advancements in rapid-deployment technologies, enabling robust humoral and cellular immunity against MPXV. Current vaccination strategies against MPXV provide foundational tools for outbreak control; however, gaps remain in accessibility, safety, and scalability. Equitable vaccine distribution and investment in research are essential to address the global mpox threat effectively.
引用
- Ortiz-Prado E, Kyriakidis NC, López-Cortés A, et al. Current and emerging Mpox vaccine strategies: A comprehensive review. Vaccine. 2025. PMID: 40784109. doi:10.1016/j.vaccine.2025.127598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。